Inhibitor outperforms rivals in leukemia, lymphoma

Print Friendly, PDF & Email


Researchers in the lab
Photo by Rhoda Baer
Preclinical research suggests the pan-FLT3/pan-BTK inhibitor CG’806 is more effective than other kinase inhibitors in fighting certain hematologic malignancies. In one study, CG’806 proved more potent than comparator drugs in primary samples of acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). In another study,... [Read Article]
Print Friendly, PDF & Email

Groups launch open portal for cancer models

Print Friendly, PDF & Email


Researcher in the lab
Photo by Darren Baker
The European Bioinformatics Institute (EMBL-EBI) and The Jackson Laboratory (JAX) have developed an open cancer research portal for patient-derived xenograft (PDX) models. The portal, known as PDX Finder, catalogues PDX models from numerous global repositories. At present, PDX Finder contains more than 1900 models for... [Read Article]
Print Friendly, PDF & Email

Antibody has ‘potent’ effects against AML

Print Friendly, PDF & Email


Micrograph showing AML
Image from Paulo
Henrique Orlandi Mourao
The bispecific antibody APVO436 has demonstrated robust T-cell activation with limited cytokine release in acute myeloid leukemia (AML), according to researchers. APVO436 binds CD123 and CD3 to redirect T-cell cytotoxicity against CD123-expressing tumor cells. Researchers found that APVO436 induced T-cell cytotoxicity in AML cells in... [Read Article]
Print Friendly, PDF & Email

Drug appears to aid chemo in AML

Print Friendly, PDF & Email


Nurse bandaging
chemotherapy patient
Photo by Rhoda Baer
Adding an experimental compound to chemotherapy is a “promising” treatment approach for certain patients with acute myeloid leukemia (AML), according to researchers. They tested the compound, CPI-613, in combination with high-dose cytarabine and mitoxantrone in a phase 1 trial of patients with relapsed or refractory AML.... [Read Article]
Print Friendly, PDF & Email

Drug shows promise for treating AML, MDS

Print Friendly, PDF & Email


Lab mouse
Preclinical results support clinical testing of an experimental agent in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), according to researchers. The agent, ALRN-6924, was shown to combat AML and MDS by restoring activity of the tumor-suppressing protein p53. ALRN-6924 exhibited antileukemic activity in AML cells and mouse models of the disease, as... [Read Article]
Print Friendly, PDF & Email

Generic antiemetic now available in US

Print Friendly, PDF & Email


Fresenius Kabi’s Palonosetron
Hydrochloride Injection
Photo from Business Wire
Palonosetron Hydrochloride Injection, a generic alternative to Aloxi®, is now available in the US. Fresenius Kabi’s Palonosetron Hydrochloride Injection is a 5-HT3 serotonin receptor that is approved for the prevention of nausea and vomiting in certain adults. Palonosetron Hydrochloride Injection is available in a single-dose... [Read Article]
Print Friendly, PDF & Email

Gene variants linked to survival after HSCT

Print Friendly, PDF & Email


DNA helix
Image by Spencer Phillips
New research has revealed a link between rare gene variants and survival after hematopoietic stem cell transplant (HSCT). Researchers performed exome sequencing in nearly 2500 HSCT recipients and their matched, unrelated donors. The sequencing revealed several gene variants—in both donors and recipients—that were significantly associated with overall survival... [Read Article]
Print Friendly, PDF & Email

Health Canada approves product for adult ALL

Print Friendly, PDF & Email


Micrograph showing ALL
Health Canada has approved inotuzumab ozogamicin (Besponsa™) as monotherapy for adults with relapsed or refractory, CD22-positive, B-cell precursor acute lymphoblastic leukemia (ALL). Inotuzumab ozogamicin is the first and only CD22-directed antibody-drug conjugate approved for this indication. The product consists of a monoclonal antibody targeting CD22 and a cytotoxic agent known as calicheamicin.... [Read Article]
Print Friendly, PDF & Email